CEO Renée Aguiar-Lucander (Calliditas)
November 9, 2020 06:56 AM ESTUpdated 05:31 PM
R&D

New­ly Nas­daq-list­ed Cal­lid­i­tas surges af­ter lead kid­ney drug hits pri­ma­ry end­point

Jason Mast

Editor

Cal­lid­i­tas still hasn’t proven to pa­tients that their kid­ney drug has long-term ben­e­fits, but the com­pa­ny says they’ve seen more than enough to go to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times